Skip to main content
PMC home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2006 Dec 5;26(10):451–454. doi: 10.1002/clc.4960261004

Rationale and design of the randomized, multicenter, Cilostazol for restenosis (CREST) trial

John S Douglas 1,✉, William S Weintraub 2, David Holmes 1
PMCID: PMC6654504  PMID: 14579914

Abstract

Restenosis of a segment of diseased coronary artery following metallic stenting is a common clinical problem and a major limitation of the procedure. Systemic pharmacologic interventions to deal with this problem have met with little success. Several small studies suggest that cilostazol, a phosphodiesterase III inhibitor whose pharmacologic properties include antiplatelet, antithrombotic, and vasodilatory effects; a beneficial effect on serum lipids; and in vitro inhibition of smooth muscle cell proliferation, may help prevent platelet aggregation and impede the accumulation of new intimal tissue in the stented artery. The Cilostazol for RESTenosis (CREST) trial will aim to evaluate more definitively the ability of cilostazol to prevent restenosis following uncomplicated stent implantation for de novo coronary artery stenosis. In this randomized, double‐blind, multicenter study, 700 patients will receive clopidogrel, aspirin, and either cilostazol or placebo after successful intracoronary stent implantation. The primary endpoint is minimal luminal diameter (MLD) of the first lesion stented after 6 months; secondary endpoints include MLD in all lesions, mean percent diameter stenosis, target lesion revascularization, and major angiographic endpoints. Safety endpoints are abnormal complete blood count and liver function tests at 1, 3, and 6 months. The trial has been initiated, and enrollment is anticipated to be concluded in 2003. Cilostazol has properties that may reduce or avert in‐stent coronary restenosis. The CREST trial is a large, rigorously conducted trial that may corroborate the favorable effects of cilostazol on coronary stent restenosis suggested by earlier studies.

Keywords: restenosis, coronary stent, cilostazol

Full Text

The Full Text of this article is available as a PDF (28.1 KB).

References

  • 1. Cowley MJ, Vetrovec GW, Wolfgang TC: Efficacy of percutaneous transluminal coronary angioplasty: Technique, patient selection, salutary results, limitations and complications. Am Heart J 1981; 101: 272–280 [DOI] [PubMed] [Google Scholar]
  • 2. Holmes DR Jr, Vlietstra RE, Smith HC, Vetrovec GW, Kent KM, Cowley MJ, Faxon DP, Gruentzig AR, Kelsey SF, Detre KM, Van Raden M, Mock M: Restenosis after percutaneous transluminal coronary angioplasty (PTCA): A report from the PTCA Registry of the National Heart, Lung, and Blood Institute. Am J Cardiol 1984; 53: 77C–81C [DOI] [PubMed] [Google Scholar]
  • 3. Weintraub WS, Kosinski AS, Brown CL III, King SB III: Can restenosis after coronary angioplasty be predicted from clinical variables? J Am Coll Cardiol 1993; 21: 6–14 [DOI] [PubMed] [Google Scholar]
  • 4. Weintraub WS, Ghazzal ZM, Douglas JS Jr, Liberman H, Morris DC, Cohen CL, King SB III: Initial management and long‐term clinical outcome of restenosis after initially successful percutaneous transluminal coronary angioplasty. Am J Cardiol 1992; 70: 47–55 [DOI] [PubMed] [Google Scholar]
  • 5. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, Detre K, Veltri L, Ricci D, Nobuyoshi M, Cleman M, Heuser R, Almond D, Teirstein PS, Fish RD, Colombo A, Brinker J, Moses J, Shankovich A, Hirshfeld J, Bailey S, Ellis S, Rake R, Goldberg S, for the Stent Restenosis Study Investigators : A randomized comparison of coronary‐stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994; 331: 496–501 [DOI] [PubMed] [Google Scholar]
  • 6. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, Emanuelsson H, Marco J, Legrand V, Materne P, Belardi J, Sigwart U, Colombo A, Goy JJ, van den Heuvel P, Delcan J, Morel M‐A, for the Benestent Study Group : A comparison of balloon‐expandable‐stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994; 331: 489–495 [DOI] [PubMed] [Google Scholar]
  • 7. Moussavian M, Casterella PJ, Teirstein PS: Restenosis after angioplasty. Curr Treatment Options Cardiovasc Med 2001; 3: 103–113 [DOI] [PubMed] [Google Scholar]
  • 8. Carrozza JP Jr, Schatz RA, George CJ, Leon MB, King SB III, Hirshfeld JW, Curry RC Jr, Ivanhoe RJ, Buchbinder M, Cleman MW, Goldberg S, Ricci D, Popma JJ, Safian RD, Baim DS: Acute and long‐term outcome after Palmaz‐Schatz stenting: Analysis from the New Approaches to Coronary Intervention (NACI) registry. Am J Cardiol 1997; 80: 78K–88K [DOI] [PubMed] [Google Scholar]
  • 9. Mintz GS, Mehran R, Waksman R, Pichard AD, Kent KM, Satler LF, Leon MB: Treatment of in‐stent restenosis. Semin Interv Cardiol 1998; 3: 117–121 [PubMed] [Google Scholar]
  • 10. Gruberg L, Waksman R: Intravascular radiation for the prevention of recurrence of restenosis in coronary arteries. Exp Opin Investig Drugs 2001; 10: 891–907 [DOI] [PubMed] [Google Scholar]
  • 11. Teirstein PS, Massullo V, Jani S, Popma JJ, Mintz GS, Russo RJ, Schatz RA, Guarneri EM, Steuterman S, Morris NB, Leon MB, Tripuraneni P: Catheter based radiotherapy to inhibit restenosis after coronary stenting. N Engl J Med 1997; 336: 1697–1703 [DOI] [PubMed] [Google Scholar]
  • 12. Gawaz M, Neumann FJ, Ott I, May A, Schomig A: Platelet activation and coronary stent implantation. Effect of antithrombotic therapy. Circulation 1996; 94: 279–285 [DOI] [PubMed] [Google Scholar]
  • 13. Schomig A, Neumann FJ, Kastrati A, Schuhlen H, Blasini R, Hadamitzky M, Walter H, Zitzmann‐Roth EM, Richardt G, Alt E, Schmitt C, Ulm K: A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary‐artery stents. N Engl J Med 1996; 334: 1084–1089 [DOI] [PubMed] [Google Scholar]
  • 14. Schuhlen H, Kastrati A, Dirschinger J, Hausleiter J, Elezi S, Wehinger A, Pache J, Hadamitzky M, Schomig A: Intracoronary stenting and risk for major adverse cardiac events during the first month. Circulation 1998; 98: 104–111 [DOI] [PubMed] [Google Scholar]
  • 15. Rosanio S, Tocchi M, Patterson C, Runge MS: Prevention of restenosis after percutaneous coronary interventions: The medical approach. Thromb Haemost 1999; 82 (suppl 1): 164–170 [PubMed] [Google Scholar]
  • 16. Monsen CH, Adams PC, Badimon L, Chesebro JH, Fuster V: Platelet‐vessel wall interactions in the development of restenosis after coronary angioplasty. Z Kardiol 1987; 76 (suppl 6): 23–28 [PubMed] [Google Scholar]
  • 17. Kimura T, Yokoi H, Nakagawa Y, Tamura T, Kaburagi S, Sawada Y, Sato Y, Yokoi H, Hamasaki N, Nosaka H, Nobuyoshi M: Three‐year follow‐up after implantation of metallic coronary‐artery stents. N Engl J Med 1996; 334: 561–566 [DOI] [PubMed] [Google Scholar]
  • 18. Sorkin EM, Markham A: Cilostazol. Drugs Aging 1999; 14: 63–71 [DOI] [PubMed] [Google Scholar]
  • 19. Tanaka T, Ishikawa T, Hagiwara M, Onoda K, Itoh H, Hidaka H: Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor, on the contraction of vascular smooth muscle. Pharmacology 1988; 36: 313–320 [DOI] [PubMed] [Google Scholar]
  • 20. Ohashi S, Iwatani M, Hyakuna Y, Morioka Y: Thermographic evaluation of the hemodynamic effect of the antithrombotic drug cilostazol in peripheral arterial occlusion. Arzneimittelforschung 1985; 35: 1203–1208 [PubMed] [Google Scholar]
  • 21. Kimura Y, Tani T, Kanbe T, Watanabe K: Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung 1985; 35: 1144–1149 [PubMed] [Google Scholar]
  • 22. Matsumoto Y, Tani T, Watanabe K, Kimura Y, Yoshikawa T: Effects of cilostazol, an antiplatelet drug, on smooth muscle cell proliferation after endothelial denudation in rats. Jpn J Pharmacol 1992; 59 (suppl 1): 284P [Google Scholar]
  • 23. Kubota Y, Kichikawa K, Uchida H, Maeda M, Nishimine K, Makutani S, Sakaguchi S, Yoshioka T, Ohishi H, Kimura Y, Yoshikawa T: Pharmacologic treatment of intimal hyperplasia after metallic stent placement in the peripheral arteries. An experimental study. Invest Radiol 1995; 30: 532–537 [DOI] [PubMed] [Google Scholar]
  • 24. Yoon Y, Shim WH, Lee DH, Pyun WB, Kim IJ, Jang Y, Cho SY: Usefulness of cilostazol versus ticlopidine in coronary artery stenting. Am J Cardiol 1999; 84: 1375–1380 [DOI] [PubMed] [Google Scholar]
  • 25. Park SW, Lee CW, Kim HS, Lee HJ, Park HK, Hong MK, Kim IJ, Park SJ: Comparison of cilostazol versus ticlopidine therapy after stent implantation. Am J Cardiol 1999; 84: 511–514 [DOI] [PubMed] [Google Scholar]
  • 26. Tsuchikane E, Fukuhara A, Kobayashi T, Kirino M, Yamasaki K, Kobayashi T, Izumi M, Otsuji S, Tateyama H, Sakurai M, Awata N: Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty. Circulation 1999; 100: 21–26 [DOI] [PubMed] [Google Scholar]
  • 27. Kunishima T, Musha H, Eto F, Iwasaki T, Nagashima J, Masui Y, So T, Nakamura T, Oohama N, Murayama M: A randomized trial of aspirin versus cilostazol therapy after successful coronary stent implantation. Clin Ther 1997; 19: 1058–1066 [DOI] [PubMed] [Google Scholar]
  • 28. Park SW, Lee CW, Kim HS, Lee NH, Nah DY, Hong MK, Kim JJ, Park SJ: Effects of cilostazol on angiographic restenosis after coronary stent placement. Am J Cardiol 2000; 86: 499–503 [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES